Search

News Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy

The authors of a study presented at the December congress of the American Society of Hematology (ASH) in Orlando introduced a new prognostic tool, m7-FLIPI, for determining the risk level of patients with follicular lymphoma (FL). They tested its utility using samples from the GALLIUM clinical trial and, during the analysis, discovered a promising biomarker that could help in selecting the primary chemotherapy for FL patients.

Source: Non-Hodgkin Lymphomas and CLL 27. 1. 2020

News Subcutaneous Immunoglobulin Substitution in Ig-Naive Patients with PID –⁠ Available Efficacy and Safety Data

The prevalence of primary immunodeficiencies (PID) is estimated at 1 : 10,000. Below, we summarize the available findings on the efficacy and safety of subcutaneous immunoglobulin substitution in Ig-naive patients (i.e., without prior immunoglobulin substitution).

Source: Primary and Secondary Immunodeficiencies 3. 4. 2023

News Long-term Efficacy, Safety, and Tolerability of Normal Human IgG with Facilitated Absorption in Patients with Humoral Immunodeficiency

The treatment of patients with humoral immunodeficiency is long-term and therefore needs to be not only effective but also safe and well-tolerated. Below, we present the outcomes from an Italian real-world clinical practice study evaluating the efficacy, safety, and tolerability of human immunoglobulin for facilitated subcutaneous administration and patient satisfaction with this therapy.

Source: Primary and Secondary Immunodeficiencies 12. 1. 2023

News Measurement of Serum Trough Levels of IgG as an Adequate and Beneficial Indicator for Assessing the Pharmacokinetics of Subcutaneously Administered Products

For many patients with primary immunodeficiency, lifelong immunoglobulin substitution is essential to reduce the frequency of severe infections. Subcutaneous home administration is better accepted by patients. However, dosing needs to be customized to the patient. The study presented below may help make therapy individualization easier for doctors and more tolerable for patients.

Source: Primary and Secondary Immunodeficiencies 11. 4. 2023

News Prognostic Model MSKCC in Patients with Metastatic Renal Carcinoma Treated in 1st Line with Sunitinib

A study by Czech authors published in 2020 demonstrated the usefulness of the MSKCC (Memorial Sloan Kettering Cancer Center) model in the prognostic stratification of patients with metastatic renal carcinoma (mRCC) treated with sunitinib in the 1st line. Additionally, a significant difference was found between the outcomes achieved in patients with intermediate risk who had one or two risk factors.

Source: Kidney Carcinoma 6. 12. 2021

News How TPO-RA Drugs Fared in Meta-Analyses of Safety and Efficacy in ITP Patients

Meta-analyses regarding the use of thrombopoietin receptor agonists (TPO-RA) evaluated their efficacy and safety in the treatment of primary immune thrombocytopenia over long-term follow-ups. What findings did they uncover?

Source: Immune Thrombocytopenia 30. 11. 2021

News Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients with Hypercholesterolemia –⁠ Meta-Analysis of 35 Randomized Controlled Trials

The authors from several American institutions examined the efficacy and safety of two proprotein convertase subtilisin/kexin type 9 (PCSK9i) inhibitors, alirocumab and evolocumab, in their work. They conducted a systematic meta-analysis of randomized controlled clinical trials comparing the administration of these two PCSK9i with standard treatment.

Source: Hypercholesterolemia 25. 11. 2021

News INTERACTIVE CASE STUDY: Treatment of glaucoma medications without preservatives –⁠ current trend

The use of glaucoma medications without preservatives has been a trend in recent years. You can try their clinical application in the role of a prescribing doctor in an interactive case study. Practical information about this popular local treatment is based on the evidence-based medicine foundation, provided by its author MUDr. Petr Výborný, CSc., from the Eye Clinic of the 1st Faculty of Medicine, Charles University and University Military Hospital in Prague.

Source: Treatment of Glaucoma 28. 9. 2023

News Risk of Venous Thromboembolism and CV Events during Targeted Treatment of Nonspecific Bowel Inflammations

Authors of a freshly published study based on real-world data from the USA investigated whether there are differences in the risk of venous thromboembolism (VTE) and major cardiovascular (CV) events in patients with nonspecific bowel inflammations (IBD) who were newly prescribed the Janus kinase inhibitor (JAK) tofacitinib or the tumor necrosis factor-alpha (TNF-α) inhibitor.

Source: Intestinal Inflammations 22. 8. 2022

Články časopisu Treatment of bleeding caused by liver cirrhosis-associated portal hypertension –⁠ update of Czech Society of Hepatology guidelines

Author of the article: T. Fejfar, T. Vaňásek, R. Brůha, P. Hůlek, V. Procházka, J. Petrtýl, J. Lata Source: Gastroenterologie a hepatologie | 2/2017 21. 4. 2017

News Lorlatinib in a Patient with Meningeal Carcinomatosis –⁠ Case Report

The prognosis of patients with meningeal carcinomatosis is unfavorable. The following case report demonstrates how a targeted mechanism of action and optimal drug penetration into the central nervous system (CNS) can not only quickly relieve patients from neurological problems associated with meningeal infiltration, but also prolong their survival.

Source: Genetic Profile and Treatment of NSCLC 6. 11. 2022

News Sotorasib in the Treatment of a Patient with NSCLC and DIC –⁠ A Case Report

Sotorasib is the first clinically used inhibitor of the KRAS oncogene with the G12C mutation. Its efficacy in the targeted treatment of non-small cell lung cancer (NSCLC) is still under research, but it is expected to bring significant benefits. The effect of sotorasib in a patient with a low baseline performance status (PS) and active brain metastases is presented in the following case report.

Source: Lung Cancer 24. 5. 2023

News EULAR 2023: What Do CRP Levels Reveal About the Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis?

What is the impact of baseline C-reactive protein (CRP) levels on the efficacy and safety of treating ankylosing spondylitis (AS) with the Janus kinase inhibitor (JAKi) tofacitinib? The authors of the cited study below sought to answer this question, with their results presented at this year’s annual EULAR congress, which took place in Milan, Italy, at the traditional turn of May and June.

Source: Arthritis 22. 8. 2023

News Recommendations for Substitution Therapy with Immunoglobulins in Hemato-oncological Patients with Secondary Immunodeficiency –⁠ Expert Consensus According to the DELPHI Methodology

Substitution therapy with immunoglobulins is used not only for patients with primary immunodeficiencies. Below, we briefly summarize recommendations concerning hemato-oncological patients with secondary immunodeficiency.

Source: Primary and Secondary Immunodeficiencies 1. 12. 2021

News How Common is Alpha-1 Antitrypsin Deficiency?

What is the prevalence of alpha-1 antitrypsin deficiency (AATD)? What comorbidities are associated with it? Are healthcare costs for these patients higher compared to patients with unrelated obstructive lung diseases? Awareness of AATD is low and prevalence data are only indicative. The authors of a study published in the European Respiratory Journal aimed to map this disease in a population of 4 million German insured individuals.

Source: Deficiency of Alpha-1-Antitrypsin 17. 12. 2020